Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2014 - 2026)

Jazz Pharmaceuticals' Long-Term Investments history runs 12 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Long-Term Investments rose 45.07% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 45.07% YoY), while the FY2025 annual figure was $1.0 billion, up 81.03% from the prior year.
• Long-Term Investments was $1.0 billion for Q1 2026 at Jazz Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.0 billion in Q4 2025 to a low of $60.0 million in Q2 2022.
• Historically, Long-Term Investments has averaged $467.1 million across 5 years, with a median of $440.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments soared 681.25% in 2024, then slipped 23.2% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $60.0 million in 2022, then soared by 100.0% to $120.0 million in 2023, then surged by 383.33% to $580.0 million in 2024, then soared by 81.03% to $1.0 billion in 2025, then fell by 1.9% to $1.0 billion in 2026.
• The last three Long-Term Investments figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $720.0 million (Q3 2025), per Business Quant data.